Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology

Thumbnail
Ver/Abrir
Versió editorial (452.5Kb)
Impacto
Compartir
Mostrar METS | MarcXML
Exportar a
Exportar a Mendeley
Metadatos
Mostrar el registro completo del ítem

comunitat-uji-handle:10234/9

comunitat-uji-handle2:10234/36080

comunitat-uji-handle3:10234/36082

comunitat-uji-handle4:

INVESTIGACION

Metadatos

Título
Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology
Autoría
 Sacristán, José Antonio;
 Lizán, Luis;
 Comellas, Marta;
 Garrido, Pilar;
 Avendaño, Cristina;
 Cruz-Hernández, Juan J.;
 Espinosa, Javier;
 Dilla, Tatiana
Fecha de publicación
2016
Editor
Springer
URI
http://hdl.handle.net/10234/165650
DOI
http://dx.doi.org/10.1007/s12325-016-0415-5
ISSN
0741-238X; 1865-8652
Cita bibliográfica
SACRISTÁN, José A., et al. Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology. Advances in Therapy, 2016, vol. 33, no 11, p. 2059-2068
Tipo de documento
info:eu-repo/semantics/article
Versión de la editorial
http://link.springer.com/article/10.1007%2Fs12325-016-0415-5
Versión
info:eu-repo/semantics/publishedVersion
Palabras clave / Materias
Resumen
Introduction The purpose of this study was to explore the main factors explaining the relative weight of the different attributes that determine the value of oncologic treatments from the different perspectives of ... [+]
Introduction The purpose of this study was to explore the main factors explaining the relative weight of the different attributes that determine the value of oncologic treatments from the different perspectives of healthcare policy makers (HCPM), oncologists, patients and the general population in Spain. Methods Structured interviews were conducted to assess: (1) the importance of the attributes on treatment choice when comparing a new cancer drug with a standard cancer treatment; (2) the importance of survival, quality of life (QoL), costs and innovation in cancer; and (3) the most worrying side effects related to cancer drugs. Results A total of 188 individuals participated in the study. For all participants, when choosing treatments, the best rated characteristics were greater efficacy, greater safety, treatment adaptation to patients’ individual requirements and the rapid reincorporation of patients to their daily activities. There were important differences among participants in their opinion about survival, QoL and cost. In general, oncologists, patients, and the general population gave greater value to gains in QoL than healthcare policy makers. Compared to other participants healthcare policy makers gave greater importance to the economic impact related to oncology treatments. Conclusions Gains in QoL, survival, safety, cost and innovation are perceived differently by different groups of stakeholders. It is recommended to consider the perspective of different stakeholders in the assessment of a new cancer drugs to obtain more informed decisions when deciding on the most appropriate treatment to use [-]
Publicado en
Advances in Therapy, 2016, vol. 33, no 11
Derechos de acceso
The Author(s) 2016
info:eu-repo/semantics/openAccess
Aparece en las colecciones

El ítem tiene asociados los siguientes ficheros de licencia:

The Author(s) 2016
Excepto si se señala otra cosa, la licencia del ítem se describe como: The Author(s) 2016